The global Cardiac Marker Testing market size accrued earnings worth approximately USD 4,300.5 Million in 2023 and is predicted to gain revenue of about USD 9,285.1 Million by 2032, is set to record a CAGR of nearly 9.05% over the period from 2024 to 2032.
Cardiac Marker Testing Market: Overview
When the heart is injured or stressed, it releases certain substances into the blood, which function as cardiac markers. The cardiac markers are usually enzymes, proteins, and hormones. Thus, quantification of these biomarkers can aid in diagnosing numerous heart disorders, including cardiac ischemia, acute coronary syndrome, and conditions linked to hindered blood supply to the heart. Physicians usually carry out multiple cardiac marker tests for hours to observe the blood level increase and to recognize the seriousness of a heart attack.
Cardiac Marker Testing Market: Definition/ Overview
Cardiac marker testing analyses specific proteins released into the bloodstream as a result of heart muscle damage or stress. Troponin, creatine kinase-MB (CK-MB), and myoglobin are indications of cardiac injury that aid in the diagnosis of a variety of cardiovascular disorders, including heart attacks, myocardial infarctions, and unstable angina. Cardiac marker testing is most commonly used for the early detection, diagnosis, and risk stratification of acute coronary syndromes, allowing healthcare providers to commence relevant therapies and interventions as soon as possible.
Furthermore, cardiac marker testing serves as essential for monitoring patients with known cardiovascular illnesses, evaluating treatment efficacy, and directing therapeutic decisions. Its broad use in emergency rooms, critical care units, and ambulatory settings demonstrates its importance in improving patient outcomes and lowering mortality rates from cardiac events.
How will Prevalence of Cardiac Illnesses Bolster Growth of Cardiac Marker Testing Market?
The global rise in cardiovascular disorders, such as heart attacks, strokes, and other heart-related conditions, is a major driver of the cardiac marker testing market. As cardiovascular disease remains one of the top causes of death worldwide, there is an increased desire for early and precise diagnosis, which can be aided by cardiac marker testing. These tests are crucial in determining the severity of heart problems and making treatment recommendations.
The development and enhancements to point-of-care testing technology have significantly impacted the cardiac marker testing market. POCT enables quick diagnostic testing at or near the point of patient care, allowing for timely decision-making and treatment commencement. POCT for cardiac markers is convenient, fast, and efficient, which benefits patients with acute coronary syndromes (ACS) and other heart problems, supporting market growth.
Furthermore, increased awareness of heart disease and its risk factors is resulting in a greater need for preventative care and early detection, including the use of cardiac markers. Also, increased worldwide healthcare expenditure, particularly in poorer nations, is increasing access to improved diagnostic tools. Governments and healthcare organizations are investing in healthcare infrastructure and services, including diagnostics, which is helping to drive the cardiac marker testing market.
Cardiac Marker Testing Market: Competitive Players
The key players in the global cardiac marker testing market include
- Siemens
- Abbott Laboratories - Lafrancol S.A.S
- Danaher Moulton
- bioMérieux Food Safety & Quality
- Alere Inc.
- Roche Diagnostics UK & Ireland
- Ortho Clinical Diagnostics
- LSI, an Avago Technologies Company Medience Corporation
- RANDOX LABORATORIES LIMITED Ltd.
- Guangzhou Wondfo Biotech Co., Ltd
- Bio-Rad Laboratories ,Inc.
- formerly Helomics
- Becton Dickenson
- BD
- Avantra Biosciences
- Enzo Biochem Inc .
Segments Covered
By Type Segment
- Troponin I and T
- Creatine kinase-MB (CK-MB)
- Brain Natriuretic peptide (Bnp or Nt-Probnp)
- Myoglobin
- HIGH-sensitivity C-reactive protein (hs-CRP)
- Other Biomarkers
By Product Segment
- InstrumentsChemiluminescenceImmunofluorescenceELISAImmunochromatography
- Reagents
- Kits
By Disease Segment
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Ischemia
By Type of Testing Segment
- Laboratory Testing Hospital Labs Refrence Labs Contract Labs
- Academic Institutions
- Point-Of-Care Testing
Cardiac Marker Testing Market: Regional Segment Analysis
- North America The U.S.Canada
- Europe France The UK Spain Germany Italy Rest of Europe
- Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific
- Latin America Brazil Mexico Rest of Latin America
- Middle East & Africa GCC South Africa Rest of Middle East & Africa